The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...
Compass Pathways (NASDAQ:CMPS) shares rose nearly 9% premarket on Friday after the biotechnology company priced a securities offering to raise up to $353M. The company is offering ~24.01M American ...
COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...
Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways is developing psilocybin as a treatment for depression. Viking ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
Hosted on MSN
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
Investors might want to bet on COMPASS Pathways PLC Sponsored ADR (CMPS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
LONDON--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common ...
American depository receipts of Compass Pathways dropped after trial results for a formulation using the psychedelic psilocybin, designed to help people with treatment-resistant depression, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results